Catalent has reached an expanded manufacturing agreement with Moderna that will quickly boost output of the company’s COVID-19 vaccine.
Under the new deal, Catalent will shift production of Moderna’s vax from two slower lines at its Bloomington, Ind. plant to one faster line — a move that will allow the facility to crank out 400 vials a minute. Ultimately the deal will be instrumental in helping Moderna meet its goal of producing 40-50 million doses per month to supply the U.S. with an additional 200 million doses by the end of July.
Catalent signed its original manufacturing agreement with Moderna last June.
Catalent is also producing J&J’s vaccine in Italy.
Read the full Wall Street Journal report.